Skip to main content

Clinical Trials Using Neoantigen Peptide Vaccine

Review the clinical trials studying neoantigen peptide vaccine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-4 of 4

Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Personalized DNA Vaccine for the Treatment of Patients with Recurrent or Refractory Pediatric Brain Tumors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Mutant-CALR Peptide Vaccine for the Treatment of Patients with CALR Mutation Positive Myeloproliferative Neoplasms
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington